Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-28, Stock:NVS, The news for the past five days is as follows:
2018-11-20: NEWS1: Gilead's Vemlidy Gets Approval in China for HBV Infection.NEWS2: Gilead's Vemlidy Gets Approval in China for HBV Infection.NEWS3: Gilead's Vemlidy Gets Approval in China for HBV Infection.NEWS4: Merck’s Stock Price Has Increased ~34% in 2018.NEWS5: CYRX: Q3 Another Very Strong Quarter With New Records in Several Categories. Operating Leverage Continues To Solidify.NEWS6: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings.NEWS7: [$$] Novartis CEO Bets on Cutting-Edge Science to Remake Drug Giant.
2018-11-21: NEWS1: This Highly Rated Pharma Giant Is More Than Just A Diabetes Player.NEWS2: Pre-Market Most Active for Nov 21, 2018 :  QQQ, AMD, GE, OMC, AAPL, SQQQ, NVS, TQQQ, NVDA, PBR, NIO, MT.NEWS3: Pre-Market Most Active for Nov 21, 2018 :  QQQ, AMD, GE, OMC, AAPL, SQQQ, NVS, TQQQ, NVDA, PBR, NIO, MT.
2018-11-23: NEWS1: US benefits manager baulks after Novartis values gene therapy at $4-5 mln.NEWS2: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS3: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS4: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS5: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS6: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS7: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS8: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS9: Novartis's pricing might be tested with costly eye therapy.NEWS10: Novartis Gets Approval for Gene Therapy Luxturna in Europe.NEWS11: U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million.NEWS12: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval.NEWS13: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval.NEWS14: Novartis : EU Approves One-time Gene Therapy Luxturna To Restore Vision.NEWS15: Novartis : EU Approves One-time Gene Therapy Luxturna To Restore Vision.
2018-11-26: NEWS1: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS2: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS3: Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss.NEWS4: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS5: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS6: Endocyte Stock Has Seen a Solid Hike in 2018.NEWS7: Health Care Digest: Genentech&apos;s blood cancer win, a boost for Gilead&apos;s HIV PrEP and a tiny IPO swings at antibiotics.NEWS8: Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies.NEWS9: Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies.NEWS10: 4 Reasons Why Lilly is Up More Than 30% This Year So Far.NEWS11: European approval of Spark Therapeutics&apos; gene therapy triggers $25M payment.
2018-11-27: NEWS1: Roche buys U.S. biotech Jecure in race for liver disease drugs.NEWS2: Novartis's Alcon sees myopia epidemic driving sales growth.NEWS3: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS4: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS5: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS6: Alcon To Highlight Vision, Strategy, Benefits As Standalone Company Post Spinoff.NEWS7: Alcon To Highlight Vision, Strategy, Benefits As Standalone Company Post Spinoff.

Answer: Rise